Published in Medical Verdicts and Law Weekly, January 18th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Peregrine Pharmaceuticals.
Report 1: Peregrine Pharmaceuticals, Inc. (PPHM) announced initiation of patient treatment in its Phase lb clinical trial to evaluate its lead antiphospholipid immunotherapy agent bavituximab given in combination with common cancer chemotherapy agents.
The trial is expected to enroll up to 12 patients at three clinical sites in India.
"We are very pleased that patient dosing is underway in this clinical study of bavituximab in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.